Welcome to our dedicated page for Inhibikase Therapeutics SEC filings (Ticker: IKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Inhibikase Therapeutics, Inc. (Nasdaq: IKT) SEC filings page on Stock Titan provides access to the company’s publicly filed regulatory documents, including current reports on Form 8-K and other submissions made through the U.S. Securities and Exchange Commission’s EDGAR system. As a clinical-stage pharmaceutical company developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease, Inhibikase uses these filings to report material corporate events, financing transactions, governance matters, and key developments in its pulmonary arterial hypertension (PAH) program.
Inhibikase’s recent 8-K filings describe, among other items, the entry into an underwriting agreement for a public offering of common stock and pre-funded warrants, the expected net proceeds from that offering, and amendments to outstanding warrants in connection with plans to advance IKT-001 to a global pivotal Phase 3 study in PAH. Other 8-Ks report financial results for specific periods, updates to corporate presentations, and outcomes of the company’s annual meeting of stockholders, including director elections, auditor ratification, and equity incentive plan amendments.
Through this page, users can review how Inhibikase discloses its clinical development strategy for IKT-001, including the planned two-part adaptive Phase 3 IMPROVE-PAH study, as well as its capital-raising activities that support ongoing research and development. Stock Titan enhances these filings with AI-powered summaries that explain the core points of lengthy documents such as current reports, shelf registration statements, and related exhibits. Investors can also monitor information related to equity offerings, warrant terms, and other securities matters that may affect the company’s capital structure.
By consolidating Inhibikase’s SEC filings and applying AI-driven analysis, this page helps readers quickly understand the regulatory and financial context surrounding the company’s PAH-focused clinical programs and broader corporate activities.
Inhibikase Therapeutics (IKT) reported a larger quarterly loss as it advanced PAH development and integrated an asset acquisition. For Q3 ended September 30, 2025, net loss was $11.93 million, driven by higher research and development expense of $7.65 million and selling, general and administrative expense of $5.61 million. Year-to-date net loss reached $35.52 million.
Liquidity remained solid, with cash, cash equivalents and marketable securities totaling about $77.3 million as of September 30, 2025. Operating cash outflow for the nine months was $20.27 million. The CorHepta acquisition was accounted for as an asset acquisition; the Company expensed acquired IPR&D of $7.36 million and recorded a contingent consideration liability of $2.42 million. IKT entered a global license for risvodetinib, receiving $1 upfront and eligibility for up to $47.5 million in milestones plus double‑digit royalties. An at‑the‑market sales agreement with Jefferies for up to $200 million was established; no sales occurred by quarter end.
Cabell Christopher filed an amended Form 3 to report ownership of 1,014,846 shares of Inhibikase Therapeutics, Inc. (IKT) common stock received as merger consideration from the acquisition of CorHepta Pharmaceuticals, Inc. Closed on 02/21/2025. Of the shares, 169,141 vested at closing, 507,423 vest on the first anniversary of closing, and the remaining 338,282 are subject to a milestone vesting schedule: 25% vests upon achievement of a specified milestone and 75% vests on the first anniversary of closing, with forfeiture of the 338,282 shares if the milestone is not achieved by that anniversary. The reporting person is identified as a director and an officer (President & Head of R&D). The amendment states these shares were inadvertently omitted from the original Form 3 filed on 02/25/2025.
Inhibikase Therapeutics director Aurentz Vincent reported beneficial ownership of 765,895 shares of common stock in an amended Form 3/A. These shares were issued as merger consideration in connection with the acquisition of CorHepta Pharmaceuticals completed on 02/21/2025 and were added to an earlier Form 3 filed 02/25/2025.
Of the 765,895 shares, 127,649 vested on the closing date, 382,947 will vest on the first anniversary of the closing date, and 255,299 are contingent: 25% of that tranche vests upon achievement of a specified milestone and 75% vests on the first anniversary, subject to continued service; if the milestone is not achieved by the first anniversary, all 255,299 shares are forfeited.
Insider share issuance tied to acquisition: This Form 4 shows director Amit Munshi received 57,265 shares of Inhibikase Therapeutics, Inc. (IKT) on 02/21/2025 as merger consideration for the acquisition of CorHepta Pharmaceuticals, Inc. Of those shares, 9,544 vested immediately on closing and 28,632 are scheduled to vest on the first anniversary of the closing. The remaining 19,089 shares are subject to a milestone-based vesting condition: 25% of that portion vests if a specified milestone is achieved and 75% vests on the first anniversary of closing, provided the reporting person continues service; if the milestone is not achieved by the first anniversary, all 19,089 shares are forfeited. The Form also discloses Mr. Munshi beneficially owns 365,000 shares indirectly through the Amit Munshi Revocable Trust. The filing is signed by an attorney-in-fact on 08/28/2025.
ADAR1 entities and manager Daniel Schneeberger report collectively holding 7,682,503 to 7,737,694 shares of Inhibikase Therapeutics, Inc. (IKT), representing 9.9% of the outstanding common stock as of June 30, 2025. The filing breaks down holdings across ADAR1 Partners, LP; Spearhead Insurance Solutions IDF, LLC; and ADAR1 SPV I, LP, and includes both issued shares and shares underlying milestone warrants. The filing also discloses that additional milestone warrants (several million shares) are excluded from beneficial ownership calculations because their exercise or exchange is subject to a 9.99% ownership limitation. The report is filed under Schedule 13G/A and is signed by Daniel Schneeberger as manager and in his individual capacity.
Inhibikase Therapeutics (IKT) reported items in its Form 10-Q showing corporate and development activity ahead of a planned Phase 2b study in pulmonary arterial hypertension (PAH). The company expects to initiate a ~150‑patient Phase 2b trial in the second half of 2025 and used non‑human primate safety studies and a bioequivalence trial in healthy volunteers to set dosing.
Financing and equity actions are material: a private placement included issuance of shares and multiple warrant tranches exercisable at $1.37 and $1.49 with exercise and ownership caps, and 19,665,131 pre‑funded warrants were outstanding at June 30, 2025. An at‑the‑market agreement with HCW was terminated effective December 11, 2024; a separate Sales Agreement with Jefferies and a related shelf registration were in place as of June 27, 2025. The company acquired CorHepta, issuing shares including contingent and performance‑based shares and recognized a $7,357,294 R&D write‑off related to IPR&D.
Inhibikase Therapeutics, Inc. filed a current report noting that it has announced its financial results for the quarter ended June 30, 2025 and provided other corporate updates through a press release. The press release is furnished as an exhibit and is not treated as part of the company’s formal, liability-bearing SEC filings unless later specifically incorporated by reference.
The company also updated its corporate presentation for use in meetings with investors, analysts and others, and furnished this presentation as a separate exhibit. Both the press release and the presentation are being shared for informational purposes under the Exchange Act without being deemed formally filed.
This Schedule 13G is filed jointly by Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC and Frank M. Sands and reports a significant passive position in Inhibikase Therapeutics common stock. The Reporting Persons beneficially own 10,950,000 shares, representing 14.7% of the outstanding class based on 74,341,540 shares outstanding as of May 1, 2025. The position is reported with shared voting and dispositive power of 10,950,000 shares and no sole voting or dispositive power.
The filing expressly excludes a Series A-1 warrant to purchase 5,475,000 shares and a Series B-1 warrant to purchase 10,068,120 shares because neither warrant is exercisable within 60 days; each warrant contains a restriction preventing beneficial ownership in excess of 19.99% immediately after exercise. The Reporting Persons certify the securities are not held to change or influence control of the issuer.
Form 4/A overview: Inhibikase Therapeutics (IKT) filed an amended Form 4 for President & Head of R&D Christopher Cabell. The filing corrects the exercise price to $2.97 on a previously reported stock-option grant covering 1,100,705 common shares originally awarded on Feb 21 2025 and expiring on Feb 21 2035. No other terms change: the options vest in three substantially equal tranches on the 2nd, 3rd and 4th anniversaries of the grant date, contingent on continued service. The amendment does not involve any share sales or purchases and therefore has no immediate cash impact on the company. It simply aligns the public record with the correct contractual terms, maintaining disclosure accuracy and avoiding potential misinterpretation of executive compensation.